BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1426 related articles for article (PubMed ID: 17875840)

  • 21. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
    Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
    Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
    De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
    Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
    Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
    Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is sentinel lymph node biopsy more accurate than axillary dissection for staging nodal involvement in breast cancer patients?
    Marrazzo A; Taormina P; Gebbiab V; David M; Riili I; Lo Gerfo D; Casà L; Noto A
    Chir Ital; 2007; 59(5):693-9. PubMed ID: 18019642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study.
    Schipper RJ; Smidt ML; van Roozendaal LM; Castro CJ; de Vries B; Heuts EM; Keymeulen KB; Wildberger JE; Lobbes MB; Beets-Tan RG
    Invest Radiol; 2013 Mar; 48(3):134-9. PubMed ID: 23262788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
    Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
    J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
    Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predictors of axillary node metastasis at breast surgery after neoadjuvant chemotherapy in patients with pre- chemotherapy-sentinel node positive breast cancer].
    Tokita H; Aruga T; Yamashita T; Saji S; Suzuki E; Horiguchi K; Kitagawa D; Sekine S; Horiguchi S; Hirashima Y; Kuroi K
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1639-45. PubMed ID: 21996959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
    Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
    Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.